Active: Treatment-resistant schizophrenia Clear all

GWAS 2023-03-01

Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data.

Pardiñas AF, Kappel DB et al.

Lancet Psychiatry

The antipsychotic, clozapine, is the only licensed drug against the treatment-resistant symptoms tha...

Plasma clozapine levels in treatment-resistant schizophrenia

4495

Participants

N/A

Studies

Details PubMed

GWAS 2022-04-07

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Okhuijsen-Pfeifer C, van der Horst MZ et al.

Transl Psychiatry

Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. H...

Symptom severity in clozapine treated schizophrenia spectrum disorders (quantitative)

684

Participants

N/A

Studies

Details PubMed

GWAS 2022-01-12

Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.

Pardiñas AF, Smart SE et al.

JAMA Psychiatry

Importance: About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respon...

Treatment-resistant schizophrenia

35043

Participants

N/A

Studies

Details PubMed

GWAS 2019-03-29

Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism.

Pardiñas AF, Nalmpanti M et al.

Am J Psychiatry

Objective: Clozapine is the only effective medication for treatment-resistant schizophrenia, but its...

Plasma norclozapine levels in treatment-resistant schizophrenia

2989

Participants

N/A

Studies

Details PubMed

GWAS 2019-01-15

A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.

Legge SE, Pardiñas AF et al.

Mol Psychiatry

Individuals of African ancestry in the United States and Europe are at increased risk of developing ...

Neutrophil level response to clozapine in treatment-resistant schizophrenia

552

Participants

N/A

Studies

Details PubMed

GWAS 2016-07-12

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.

Legge SE, Hamshere ML et al.

Mol Psychiatry

The antipsychotic clozapine is uniquely effective in the management of schizophrenia; however, its u...

Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia

Replicated

7006

Participants

N/A

Studies

Details PubMed

GWAS 2016-02-11

Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population.

Saito T, Ikeda M et al.

Biol Psychiatry

Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-th...

Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia

2955

Participants

N/A

Studies

Details PubMed

GWAS 2015-02-05

Genome-wide association study of lymphoblast cell viability after clozapine exposure.

de With SA, Pulit SL et al.

Am J Med Genet B Neuropsychiatr Genet

Clozapine is an antipsychotic drug with proven efficacy in treatment-resistant schizophrenia but als...

Clozapine-induced cytotoxicity

Participants

N/A

Studies

Details PubMed

Title

Author

Journal

Disease/Trait

Date

Actions

Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data.

Pardiñas AF, Kappel DB et al.

Lancet Psychiatry

Plasma clozapine levels in treatment-resistant schizophrenia

2023-03-01

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Okhuijsen-Pfeifer C, van der Horst MZ et al.

Transl Psychiatry

Symptom severity in clozapine treated schizophrenia spectrum disorders (quantitative)

2022-04-07

Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.

Pardiñas AF, Smart SE et al.

JAMA Psychiatry

Treatment-resistant schizophrenia

2022-01-12

Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism.

Pardiñas AF, Nalmpanti M et al.

Am J Psychiatry

Plasma norclozapine levels in treatment-resistant schizophrenia

2019-03-29

A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.

Legge SE, Pardiñas AF et al.

Mol Psychiatry

Neutrophil level response to clozapine in treatment-resistant schizophrenia

2019-01-15

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.

Legge SE, Hamshere ML et al.

Mol Psychiatry

Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia

2016-07-12

Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population.

Saito T, Ikeda M et al.

Biol Psychiatry

Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia

2016-02-11

Genome-wide association study of lymphoblast cell viability after clozapine exposure.

de With SA, Pulit SL et al.

Am J Med Genet B Neuropsychiatr Genet

Clozapine-induced cytotoxicity

2015-02-05